Inflammatory Bowel Disease

FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR

NCT00810030 | PHASE 3 | INTERVENTIONAL

The purpose of this study is to determine how safe, tolerable and effective the new standardised dosage regimen of FERINJECT® infusions is, compared with a well established intravenous iron treatment.

1 Sites

484 Participants

Recruiting

18 Years to 65 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

AKH Vienna, University clinic of Int Medizin III

Vienna,Austria,1090

Study Eligibility Criteria

Inclusion Criteria

* Males or non-pregnant females aged ≥ 18 years at the time of vaccination.
* Females of child-bearing potential (i.e., ovulating, pre-menopausal, not surgically sterile) must be abstinent or be willing to use a medically accepted contraceptive regimen for the duration of the On-study period. Females of child-bearing potential must return a negative urine pregnancy test result prior to vaccination with the vaccine.

Exclusion Criteria

* Known hypersensitivity to a previous dose of influenza vaccine or allergy to eggs, chicken protein, neomycin, polymyxin, or any components of bioCSL influenza vaccines.
* Vaccination against influenza in the previous 6 months.
* Known history of Guillain-Barré Syndrome or other demyelinating disease.
* Clinical signs of active infection and/or an oral temperature of ≥ 100.4°F (38.0°C).
* A clinically significant medical condition.
* Pregnant or lactating females.

Additional Studies

Additional studies can be found at ClinicalTrials.gov